Clinical trials: Cardiac Allograft Vasculopathy
Coronary Artery Disease in Transplanted Heart (Diagnosis), Platelet Dysfunction
Coronary Artery Disease After Heart Transplantation
This study evaluates coronary artery disease after heart transplantation and its relation to platelet function. Furthermore, we will evaluate extracorporeal photopheresis as treatment of coronary artery disease after heart…
- Trial name
- ECP (NCT03583229)
- Testing
- Aspirin 75mg, Extracorporeal photopheresis
- Where
- Denmark
- Volunteers
- 70 people
- Sponsor
- Aarhus University Hospital
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Cardiac Allograft Vasculopathy, Chronic Rejection of Cardiac Transplant
Heart Failure After Heart Transplantation Due to Chronic Rejection
This study will investigate the prevalence of allograft vasculopathy and unexplained graft dysfunction during long-term follow-up after heart transplantation. Risk factors as well diagnostic approaches will be investigated.
- Conditions
- Cardiac Allograft Vasculopathy, Chronic Rejection of Cardiac Transplant, Graft Dysfunction
- Trial name
- AVALON (NCT03808324)
- Testing
- Diagnostic investigations
- Where
- Sweden
- Volunteers
- 100 people
- Sponsor
- Sahlgrenska University Hospital
Heart Transplanted Patients, Lung Transplanted Patients
Unraveling Mechanism of Action of Extracorporeal Photopheresis in Heart and Lung Transplant Patients
This is a prospective observational single center national study. Lung and heart transplant patients with a definite diagnosis of chronic lung allograft dysfunction (CLAD) or cardiac allograft vasculopathy (CAV) will be assigned…
- Conditions
- Heart Transplanted Patients, Lung Transplanted Patients, Chronic Lung Allograft Dysfunction (CLAD), Cardiac Allograft Vasculopathy
- Trial name
- URRAH (NCT06899828)
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Heart Transplant
Impact of Evolocumab in Cardiac Transplant Patients With CAV
Coronary allograft vasculopathy (CAV) is diffusely accelerated atherosclerosis of a transplanted heart. Evolocumab (Repatha) is an FDA-approved drug for lowering low density lipoprotein (LDL) in patients who have not received a…
- Trial name
- NCT03944577
- Testing
- Evolocumab
- Where
- United States
- Volunteers
- 26 people
- Sponsor
- University of Nebraska
Cardiac Allograft Vasculopathy
Endothelin-1 and Cardiac Allograft Vasculopathy (CAV)
Many patients with end-stage heart failure, a condition in which the heart fails to pump enough blood to support the body's other organs, are fortunate enough to receive a heart transplant.
- Trial name
- NCT05373108
- Testing
- Macitentan
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- University of California, Los Angeles
Heart Transplant Failure and Rejection, Magnetic Resonance Imaging
Heart TIMING - Heart Transplantation IMagING
The cardiac allograft rejection (CAR) and cardiac allograft vasculopathy (CAV) significantly affect the prognosis of patients after heart transplantation.
- Trial name
- NCT03499197
- Testing
- cardiac magnetic resonance imaging
- Where
- Hungary
- Volunteers
- 100 people
- Sponsor
- Semmelweis University Heart and Vascular Center
Cardiac Allograft Vasculopathy
MARINER Trial: Multiparametric Cardiac PET for CAV Surveillance After Heart Transplantation
Cardiac allograft vasculopathy (CAV) is a common complication affecting heart transplant patients. This condition causes narrowing of the heart arteries leading to graft dysfunction.
- Trial name
- NCT06089486
- Testing
- ICA, PET
- Where
- 5 sites in Canada
- Volunteers
- 576 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Transplant, Acute Graft Rejection
Stress Cardiac MRI for Evaluation of Nonspecific Allograft Dysfunction
The investigators will use cardiac MRI to measure the myocardial perfusion reserve and amount of myocardial edema and fibrosis in heart-transplant patients with nonspecific allograft dysfunction in contrast to those with normal…
- Conditions
- Heart Transplant, Acute Graft Rejection, Chronic Graft Rejection
- Trial name
- NCT02597543
- Testing
- Regadenoson, Gadolinium, Cardiac MRI
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Paul Kim
Cardiac Allograft Vasculopathy
Phosphodiesterase-5 (PDE-5) Inhibition in Heart Transplant Recipients
Hypothesis 1: Treatment of heart transplant recipients with sildenafil, a PDE-5 inhibitor, will improve small artery elasticity (SAE) when compared to placebo.
- Trial name
- NCT01812434
- Testing
- Sildenafil
- Where
- United States
- Sponsor
- University of Minnesota
Cardiac Allograft Vasculopathy
Early Post Transplant Cardiac Allograft Vasculopathy
Heart transplantation is an effective life-saving treatment for patients with end-stage heart disease. After a transplant, the new heart may develop narrowing in the arteries, causing heart failure, heart attacks and abnormal…
- Trial name
- ECAV (NCT03217786)
- Where
- Canada
- Volunteers
- 80 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Heart Transplant Recipients
Autonomic Cardiovascular Control After Heart Transplantation
The purpose of this prospective study is to investigate denervation (ie. surgical cutting of autonomic nerves) and re-innervation (ie. growth of autonomic nerves) in heart transplant recipients. More specifically, we focus on: 1.
- Trial name
- AccHeart (NCT01759966)
- Where
- Norway
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Oslo University Hospital
Cardiac Allograft Vasculopathy
A Study to Compare the Effectiveness of a Drug That Suppresses the Immune System Called Thymoglobulin® in Preventing the Development of a Disease That Affects the Majority of Heart Transplant Recipients Called Cardiac Allograft Vasculopathy (CAV)
The purpose of this study is to test the hypothesis that administering Thymoglobulin® induction therapy early after transplant prevents the development of cardiac allograft vasculopathy (CAV).
- Trial name
- NCT01157949
- Testing
- Thymoglobulin
- Where
- United States
- Sponsor
- Cedars-Sinai Medical Center
Cardiac Allograft Vasculopathy
Safety and Efficacy of Everolimus - Eluting Bioresorbable Vascular Scaffold for Cardiac Allograft Vasculopathy
The CART Pilot study was designed to provide preliminary observations (about performance and safety) and generate hypotheses for future studies .
- Trial name
- CART (NCT02377648)
- Testing
- Everolimus-Eluting Bioresorbable Vascular Scaffold (ABSORB)
- Where
- 10 sites in Italy, Netherlands
- Volunteers
- 34 people
- Sponsor
- Universita di Verona
Cardiac Allograft Vasculopathy
Clinical Trial of Pioglitazone for Prevention of Cardiac Allograft Vasculopathy After Heart Transplantation
The purpose of this study is to determine the benefit of using the FDA-approved insulin-sensitizing agent, Pioglitazone, on human heart transplant recipients.
- Trial name
- NCT01186250
- Testing
- Pioglitazone
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Stanford University
Cardiac Allograft Vasculopathy, Antibody Mediated Rejection
Endothelial Injury and Development of Coronary Intimal Thickening After Heart Transplantation
Coronary allograft vasculopathy (CAV) is the leading cause of late graft failure and second leading cause of late mortality after heart transplantation.
- Trial name
- NCT01848301
- Testing
- Optical Coherence Tomography, Acetylcholine, Brachial Artery Flow Mediated Dilation
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Gladwin, Mark, MD
Renal Function and Chronic Allograft Vasculopathy
SCHEDULE - Scandinavian Heart Transplant Everolimus de Novo Study With Early Calcineurin Inhibitor (CNI) Avoidance
A controlled, randomized, open-label, multicenter study evaluating if early initiation of everolimus and early elimination of cyclosporine in de novo heart transplant recipients can improve long-term renal function and slow down…
- Trial name
- SCHEDULE (NCT01266148)
- Testing
- Cyclosporine, Mycophenolate mofetil, Corticosteroids
- Where
- 6 sites in Denmark, Norway and 1 more
- Volunteers
- 115 people
- Sponsor
- Novartis Pharmaceuticals
Heart Transplantation
The Association of Endothelial Dysfunction and Cardiac Allograft Vasculopathy
Progressive cardiac allograft vasculopathy (CAV) is a serious complication in long-term survivors after heart transplantation. Therefore, we hypothesize that CAV is a diffuse and progressive process, and endothelial function may…
- Trial name
- NCT00173914
- Where
- Taiwan
- Volunteers
- 100 people
- Sponsor
- National Taiwan University Hospital
Cardiac Allograft Vasculopathy, Acute Cellular Graft Rejection
Cardiac Mitochondrial Function After Heart Transplantation
Studies have shown that cardiac function is affected immediately after heart transplantation (HTx), but seems to recover to some extent over the first year.
- Conditions
- Cardiac Allograft Vasculopathy, Acute Cellular Graft Rejection, Primary Graft Failure, Mitochondrial Function
- Trial name
- ENERGY-HTX (NCT04105803)
- Where
- Denmark
- Volunteers
- 64 people
- Sponsor
- University of Aarhus
Cardiac Allograft Vasculopathy
Efficacy and Safety Of Alirocumab to Prevent Early Cardiac Allograft Vasculopathy in Recent Heart Transplant Recipients
Cardiac allograft vasculopathy (CAV) represents the leading cause of late morbidity and mortality in heart transplant recipients as the second most frequent cause of all deaths at 3 years.
- Trial name
- ACAV (NCT04193306)
- Testing
- Alirocumab
- Where
- Czechia
- Volunteers
- 126 people
- Sponsor
- Institute for Clinical and Experimental Medicine